文献速递脑血管病神经重症与神经感染

持续性组织水平低灌注(无复流)抵消成功取栓的临床获益

Persistent Tissue-Level Hypoperfusion (No-Reflow) Negates the Clinical Benefit of Successful Thrombectomy.
PubMed 文献 · Stroke · 2025-03-31

该研究为EXTEND-IA与EXTEND-IA TNK 1和2试验的事后汇总分析,纳入456例患者,比较无复流(eTICI 2c3-NoReflow)与完全复流、部分再通及取栓失败患者的结局。结果显示无复流患者90天功能独立率与取栓失败者相似,且梗死体积大于完全复流者,提示预防或逆转无复流可能增强再灌注治疗的临床获益。

要点

  • 无复流定义为尽管eTICI 2c-3再通,24小时灌注CT/MRI显示梗死区相对脑血流量或体积较对侧同源区降低>15%。
  • eTICI 2c3-NoReflow患者90天良好结局率为43.33%(13/30),低于eTICI 2c3-CompleteFlow的67.50%(81/120)。
  • 多变量分析中,无复流患者良好结局的校正OR为0.31(95%CI 0.12-0.77;P=0.01)对比完全复流。

核心结论

  • 当发生无复流时,尽管血管造影完全再通,患者的临床和影像结局与取栓失败者相似。
  • 预防或逆转无复流有可能增强缺血性卒中再灌注治疗的临床获益。

研究设计与样本

  • EXTEND-IA和EXTEND-IA TNK第1和第2部分试验的事后汇总分析。
  • 从总体汇总队列537例患者中纳入456例进行分析。
  • 纳入患者平均年龄71岁,54%为男性。
  • 比较四组:eTICI 2c3-NoReflow、eTICI 2c3-CompleteFlow、eTICI 2b和取栓失败(eTICI 0-2a)。
  • 主要结局为90天功能独立,采用混合效应逻辑回归模型分析,未校正和校正预先选择的协变量(年龄、病前改良Rankin量表评分、基线美国国立卫生研究院卒中量表评分和基线核心梗死体积)。

主要发现

  • 90天良好结局(改良Rankin量表评分0-2分或恢复至基线改良Rankin量表评分)率:eTICI 2c3-NoReflow组43.33%(13/30),eTICI 2c3-CompleteFlow组67.50%(81/120),eTICI 2b组63.03%(150/238),取栓失败组50.00%(34/68)。
  • 多变量分析中,eTICI 2c3-NoReflow患者良好结局的校正OR为0.31(95%CI 0.12-0.77;P=0.01)对比eTICI 2c3-CompleteFlow,校正OR为0.40(95%CI 0.17-0.96;P=0.04)对比eTICI 2b,但与取栓失败相比无显著差异(校正OR 1.02,95%CI 0.38-2.73;P=0.97)。
  • eTICI 2c3-NoReflow患者随访梗死体积与取栓失败者相似(β=-8.26,95%CI -27.38至10.86;P=0.40),与eTICI 2b组相似(β=9.38,95%CI -7.33至26.09;P=0.27),但梗死体积大于eTICI 2c3-CompleteFlow组(β=18.85,95%CI 1.16-36.54;P=0.04)。

关键数值与推荐

  • 无复流(eTICI 2c3-NoReflow)定义为尽管eTICI 2c-3血管造影再通,24小时随访灌注CT或MRI显示梗死区相对脑血流量或体积较对侧同源区降低>15%。
  • 完全再通并组织复流(eTICI 2c3-CompleteFlow)定义为eTICI 2c-3再通且无上述无复流标准。
  • 部分再通(eTICI 2b)和取栓失败(eTICI 0-2a)按血管造影分级定义。
  • 主要结局为90天功能独立(改良Rankin量表评分0-2分或恢复至基线改良Rankin量表评分)。

临床怎么用

  • 原文结论指出预防或逆转无复流有可能增强缺血性卒中再灌注治疗的临床获益。
  • 原文未据此给出具体临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tissue-level hypoperfusion (no-reflow) persists in 30% of patients with seemingly successful upstream angiographic recanalization at thrombectomy. We investigated the clinical impact of the no-reflow phenomenon by comparing patients with no-reflow versus patients with varying degrees of angiographic recanalization. METHODS: In a post hoc pooled analysis of the EXTEND-IA (Endovascular Therapy for Ischemic Stroke With Perfusion-Imaging Selection) and EXTEND-IA TNK (Tenecteplase Versus Alteplase Before Thrombectomy for Ischemic Stroke) part 1 and 2 trials, clinical and radiological outcomes were compared between patients with (1) full angiographic recanalization with no-reflow (extended Thrombolysis in Cerebral Infarction [eTICI] 2c3-NoReflow), defined as >15% reduction in relative cerebral blood flow or Volume within the infarct relative to a contralateral homolog on 24-hour-follow-up perfusion computed tomography or magnetic resonance imaging despite eTICI grade 2c-3 angiographic recanalization, (2) full angiographic recanalization and tissue reperfusion (eTICI 2c3-CompleteFlow), (3) partial angiographic recanalization (eTICI 2b), and (4) unsuccessful thrombectomy (eTICI 0-2a). The primary outcome, functional independence at 90 days, was investigated using a mixed effect logistic regression model, both unadjusted and adjusted for a priori-selected covariates, namely age, premorbid modified Rankin Scale, baseline National Institutes of Health Stroke Scale, and baseline core volume. RESULTS: Among 537 patients from the overall pooled cohort, 456 patients were included in the analysis. The mean age of the included patients was 71 years old, and 54% were male. A favorable outcome (90-day modified Rankin Scale score of 0-2 or return to baseline modified Rankin Scale) was observed in 43.33% (n=13/30) of patients with eTICI 2c3-NoReflow, 67.50% (n=81/120) of eTICI 2c3-CompleteFlow, 63.03% (n=150/238) of eTICI 2b, and 50.00% (n=34/68) of unsuccessful thrombectomy. In multivariable analysis, patients with eTICI 2c3-NoReflow had lower odds of favorable outcome compared with those with eTICI 2c3-CompleteFlow (adjusted odds ratio, 0.31 [95% CI, 0.12-0.77]; P=0.01) and eTICI 2b (adjusted odds ratio, 0.40 [95% CI, 0.17-0.96]; P=0.04) but not unsuccessful thrombectomy (adjusted odds ratio, 1.02 [95% CI, 0.38-2.73]; P=0.97). Patients with eTICI 2c3-NoReflow had similar follow-up infarct volume to unsuccessful thrombectomy (β=-8.26 [95% CI, -27.38 to 10.86]; P=0.40) and eTICI 2b (β=9.38 [95% CI, -7.33 to 26.09]; P=0.27) but had larger infarcts compared with eTICI 2c3-CompleteFlow (β=18.85 [95% CI, 1.16-36.54]; P=0.04). CONCLUSIONS: When no-reflow occurred, clinical and radiological outcomes in patients with full angiographic recanalization were similar to patients with unsuccessful thrombectomy. Preventing or reversing no-reflow has the potential to augment the clinical benefit of reperfusion treatment in ischemic stroke.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Rivet S, Churilov L, Yassi N, et al. Persistent Tissue-Level Hypoperfusion (No-Reflow) Negates the Clinical Benefit of Successful Thrombectomy. Stroke. 2025. PMID: 40160088. doi:10.1161/STROKEAHA.124.049574

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。